Development of myopia control treatments to improve socio-economic aspects of myopic patients

Cross-sectional and longitudinal studies have highlighted differences in the speed and accuracy of focussing during near-work between myopes and non-myopes as well as asymmetry in the effects of blur in myopes and non-myopes. This led to the design of a dual treatment for myopia control and a subsequent clinical trial of this treatment. The novel treatment for improving accommodative accuracy and dynamics in young persons with myopia has demonstrated that treatments were effective in modifying accommodation leading to a slowing down of myopia in six months.

The patent for the contact lens designed as part of this clinical trial has been filed in several countries. This novel contact lens design patent would be held jointly with VisionCRC, UNSW, Australia who have industrial partners in the contact lens area (Ciba Vision, Novartis). VERU's research collaborators have also undertaken other clinical trials of treatments for myopia control.

Future impact in this area is likely to result from both the combination of treatments supported by further basic research to understand the adaptation to treatments resulting in reduced efficacy a few months after initiation. In addition, our studies on the progression of myopia, looking beyond optical factors to consider a range of influences including family history, IQ and near-work has been important in assessing the progression of myopia in non-UK cohorts.